Original articleSystematic review of the epidemiologic and trial evidence of an association between antidepressant medication and breast cancer
Introduction
Breast cancer is the commonest malignancy in women worldwide, accounting for nearly one-fifth of all female cancers [1]. Antidepressant drug use is also common, and is increasing 2, 3. Biological studies, conducted in the 1990s, suggested that both tricyclic and serotonin reuptake inhibitor (SSRI) antidepressants may increase breast cancer risk or promote tumor growth [4]. These findings created alarm in the medical and popular press 5, 6. Animal studies performed by scientists working for a pharmaceutical company that produces fluoxetine, an SSRI, found no evidence of increased risk with this drug [7].
Biological plausibility for an association comes from animal and laboratory studies that show that both tricyclic and SSRI antidepressants are chemically similar to an antioestrogen binding site that stimulates breast cancer growth in animals [4], inhibits lymphocyte proliferation [4], and stimulates secretion of prolactin from the pituitary gland 8, 9. However, the therapeutic and side-effect profiles of antidepressants indicate that they influence a number of different biological pathways, and some researchers have suggested that they may even have antitumor potential because they inhibit cellular proliferation [10].
Findings from animal studies may not be relevant to humans, but media reports from these, without good evidence to refute the findings, may lead to inappropriate changes in prescribing behavior for women with depression. On the other hand, given the widespread and increasing use of antidepressants, if there were an association between antidepressant use and breast cancer this would have important public health implications. Therefore, it is essential that evidence of an association between antidepressants and breast cancer is sought in studies of women. Two recently published studies—a community-based case–control study [11] and a prospective cohort study [12]—found conflicting results concerning the association between antidepressant use and breast cancer, the former reporting no association and the latter a positive association. Neither study undertook a systematic review of the available evidence to examine the direction of association in all other studies that have been conducted. In this article we summariae all available evidence from trials and epidemiological studies.
Section snippets
Data sources
We searched Medline (1966–June 2002), Embase (1980–June 2002), PsycLit (1981–June 2002), Science Citation's Index (1975–June 2002), and the Cochrane Database of Systematic Reviews and Controlled Trials Register (2001 issue 1) using Medical Subject Headings (MeSH) and free text terms where appropriate. We combined the terms “antidepressive agents,” “serotonin (re)uptake inhibitors,” “tricyclic, monoamine oxidase inhibitors,” and the generic names of all antidepressant drugs included in chapter
Results
In this section we have included descriptions of the methodologic strengths and weaknesses of each study. The likely impact of these on study results are discussed more fully in the discussion section of the article.
The results of the literature search are presented in Figure 1. Details from primary efficacy trials from one drug company, two prospective and two retrospective cohort studies, and four case control studies were analyzed (Table 1). Figure 2 shows the effect sizes from each study.
Discussion
The suspected association, based on animal studies, between antidepressant use and breast cancer cannot be confirmed with current epidemiologic evidence. Most studies found no association between antidepressant use and breast cancer risk.
A positive association was found in one prospective cohort study [12]. Exposure misclassification in this study is unlikely to be linked to breast cancer occurrence (i.e., it is nondifferential), and therefore, would most likely bias the estimate towards the
Acknowledgments
We thank Gary D Friedman, Division of Research, Kaiser Permanent Medical Care Programme, Northern California, who provided additional data from the Kaiser Permanent drugs screening cohort, and Eli-Lily Pharmaceuticals for provision of their trial data and permission to use this in our review. Richard Martin and Klim McPherson, Department of Social Medicine, University of Bristol, provided useful comments on earlier drafts of the article. There were no conflicts of interest in this article. D.A.
References (31)
The effect of a serotonin uptake inhibitor (Lilly 110140) on the sercretion of prolactin in the rat
Life Sci
(1975)- et al.
Effects of psychotropic drugs on cell proliferation and differentiation
Biochem Pharmacol
(1999) - et al.
Antidepressant use and the risk of breast cancera non-association
J Clin Epidemiol
(2001) - et al.
Major depression in womena review of the literature
J Am Pharm Assoc (Wash)
(2000) - et al.
ABC of breast diseases. Breast cancer—epidemiology, risk factors, and genetics
BMJ
(2000) - et al.
Recent trends in the use of antidepressant drugs in Australia, 1990–1998
Med J Aust
(2000) - et al.
General practitioners' perceptions of the tolerability of antidepressant drugsa comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants
BMJ
(1997) - et al.
Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses
Cancer Res
(1992) Do antidepressants promote tumors?
Science
(1992)Backfire. Could Prozac and Elavil promote tumor growth?
Sci Am
(1994)
Carcinogenicity studies of fluoxetine hydrochloride in rats and mice
Cancer Res
Prolactin secretion in patients treated with various drugsphenothiazines, tricyclic antidepressants, reserpine, and methyldopa
Arch Intern Med
Antidepressant medication use and breast cancer risk
Am J Epidemiol
Psychotropic medication use and risk of hormone-related cancersThe New York University Women's Health Study
J Pub Health Med
The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions
J Epidemiol Community Health
Cited by (50)
A new risk of bias checklist applicable to randomized trials, observational studies, and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events
2017, Journal of Clinical EpidemiologyCitation Excerpt :In general, risk of bias assessment of studies included, in systematic reviews of adverse drug events, is poorly reported [18,19]. When reported, the authors usually measure the quality of the studies by either using multiple tools (e.g., combining the Cochrane Risk of Bias Tool and the McHarm scale) [20] or by building new and not formally validated tools to assess specific drug adverse effects [21–24]. Furthermore, instead of checklists, the use of rating scales has been shown to be not adequate for risk of bias assessment [25].
Associations between DSM-IV mental disorders and subsequent self-reported diagnosis of cancer
2014, Journal of Psychosomatic ResearchIs amisulpride safe when prescribed to breast and prostate cancer patients?
2013, Medical HypothesesCitation Excerpt :The systematic review of epidemiological evidence done some years ago by Bahl et al. found that a modest association between antidepressant and breast cancer cannot be excluded [1]. A similar review, conducted in the same period by Lawlor et al., concluded that epidemiologic evidence does not support an association between antidepressants and breast cancer [36]. It is noteworthy adding that in a study by Cosgrove [37] on antidepressants linked to breast and ovarian cancers, researchers with industry affiliations were found to be significantly less likely (0/15) to conclude that antidepressants increase the risk of breast or ovarian cancer (p = .0012, Fisher exact), compared to researchers without said ties (20/46).
Management of hot flushes for breast cancer survivors
2012, Gynecologie Obstetrique et FertilitePsychiatric disorders among cancer patients
2012, Handbook of Clinical NeurologyOral administration of fluoxetine alters the proliferation/apoptosis balance of lymphoma cells and up-regulates T cell immunity in tumor-bearing mice
2011, European Journal of PharmacologyCitation Excerpt :Cancer patients are often co-treated with antidepressants to alleviate their mood disorders, such as depression and dysthymia. However, clinical studies did not provide solid evidences pointing to the effects of antidepressant administration on tumor progression (Coogan et al., 2005, 2009; Steingart and Cotterchio, 1995; Lawlor et al., 2003). Several studies have demonstrated that some antidepressants can affect tumor cells viability.